ALSO NOTED: Canada's drug market slowing; GSK files for Promacta approval;

> The Canadian pharma market has slowed to a growth level of 6 percent to 6.5 percent, down from a five-year average of 8.4 percent. Report

> GlaxoSmithKline submitted an NDA for Promacta, a platelet growth factor designed to treat thrombocytopenic purpura. Report

> Valeant Pharmaceuticals says it will sell its hepatitis C drug Infergen to Three Rivers Pharmaceuticals doe about $91.3 million. Report

> Par Pharmaceutical says its year-end profits will be at least $1.45 per share; previously, the generics maker had said it expected earnings of $1.35 to $1.50. Report

> Idera is pocketing a $40 million up front fee from Merck KGaA and hopes to make an additional $381 million in milestones from licensing its technology for cancer therapies. Report

> In a deal that starts small but has a big upside, Santaris Pharma has forged a $700 million development pact with GlaxoSmithKline to develop new antiviral meds. Report

> Boston-based venture capitalist Roger Kitterman has been able to coax investors to back badly needed therapies with none of the big upside that most would demand. Report

> The Wall Street Journal health blog pokes fun at Bystolic, the newly-approved beta blocker from Forest Laboratories and Mylan, as the ultimate "me-too" drug. Report

And Finally… Harvard Business School researchers have identified four types of healthcare consumers, each of which responds to entirely different marketing approaches. Report

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.